0JQ2 Stock Chart & Stats
$0.70
$0.07(10.35%)
At close: 4:00 PM EDT
$0.70
$0.07(10.35%)
Day’s Range― - ―
52-Week Range$0.37 - $95.25
Previous CloseN/A
Volume2.44K
Average Volume (3M)68.70K
Market Cap
$8.11M
Enterprise Value-$7.10
Total Cash (Recent Filing)$7.23M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.11
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.34%
Share Statistics
EPS (TTM)N/A
Shares Outstanding19,339,787
10 Day Avg. Volume175,376
30 Day Avg. Volume68,696
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-0.14
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Deleveraged Balance SheetEliminating debt materially reduces leverage and interest-related pressure compared with prior years, improving financial flexibility. Positive equity also provides some balance-sheet support, although the cushion remains modest relative to the company’s continuing cash needs.
Loss ReductionA lower net loss indicates some improvement in financial performance and could moderate the pace of capital consumption if sustained. However, the company remains far from break-even, so this is a limited positive rather than evidence of an established profitable operating model.
Ophthalmic Testing Distribution OpportunityThe five-year exclusive distribution arrangement gives Kala a defined commercial role in ophthalmic genetic testing and creates a potential pathway to diversify beyond its historical development focus. Commercial development responsibility and a profit split may support future revenue if adoption milestones are achieved.
Bears Say
Near-zero Revenue And Persistent LossesThe absence of a meaningful revenue base shows that Kala has not yet established operating scale or recurring commercial economics. Persistent losses limit internal funding capacity and make future progress dependent on successful commercialization, partnerships, or additional external capital.
Material Cash Burn And Financing DependenceContinued negative cash generation means the business is consuming liquidity rather than funding itself through operations. This increases dependence on financing and leaves less flexibility to sustain development or commercial initiatives if capital markets become less available.
Nasdaq Listing UncertaintyPotential suspension or delisting could reduce trading liquidity and institutional participation, making it harder for Kala to access public-market capital and maintain investor visibility. The uncertainty is especially material for a company already reliant on external funding.
KALA BIO News
0JQ2 FAQ
What was KALA BIO’s price range in the past 12 months?
KALA BIO lowest share price was $0.37 and its highest was $95.25 in the past 12 months.
What is KALA BIO’s market cap?
KALA BIO’s market cap is $8.11M.
When is KALA BIO’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were KALA BIO’s earnings last quarter?
Currently, no data Available
Is KALA BIO overvalued?
According to Wall Street analysts KALA BIO’s price is currently Overvalued.
Does KALA BIO pay dividends?
KALA BIO pays a Notavailable dividend of $0.285 which represents an annual dividend yield of 0.34%. See more information on KALA BIO dividends here
What is KALA BIO’s EPS estimate?
KALA BIO’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KALA BIO have?
KALA BIO has 19,339,787 shares outstanding.
What happened to KALA BIO’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of KALA BIO?
Currently, no hedge funds are holding shares in GB:0JQ2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KALA BIO
Kala Bio, Inc. functions as a biopharmaceutical company dedicated to the creation and commercialization of new therapeutic solutions. The core of their strategy involves utilizing proprietary nanoparticle technology, specifically mucus penetrating particles (MPPs). Initially, their focus for these treatments is directed towards ophthalmic diseases. The company was established in 2009 by co-founders Justin Hanes, Robert S. Langer, and Colin R. Gardner, and its headquarters are located in Arlington, Massachusetts.
Technical Analysis
Daré Bioscience
―
Vyome Holdings
―
Citius Pharmaceuticals
―
Lexaria Bioscience
―
Exicure
―